Neovasculgen

Neovasculgen is a gene-therapy drug for treatment of peripheral artery disease , including critical limb ischemia ; it delivers the gene encoding for vascular endothelial growth factor(VEGF). [1] [2] Neovasculogen is a plasmid encoding the CMV promoter and the amino acid 165 form of VEGF. [3] [4] It was developed by the Human Stem Cells Institute in Russia and approved in Russia in 2011.